GlassScriptPhysician profile
Joseph T Ayoub
NPI 1902888365
$19,308.95
in general payments reported to CMS, 2019-2025
39 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $4,218 · 2021: $3,276 · 2022: $2,845 · 2023: $4,169 · 2024: $2,009 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,309 · Travel and Lodging: $2,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,309.02 |
| Travel and Lodging | $2,284.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $10,204.90 | 2021-2025 | Diamondtemp Bidirectional Ablation Catheter, Micra, Linq II |
| Medtronic Vascular, INC. | $3,871.74 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $623.51 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $591.85 | 2019-2023 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $528.27 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $476.12 | 2019-2024 | Xarelto |
| Amgen INC. | $414.89 | 2020-2025 | Repatha |
| Pfizer INC. | $297.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $250.60 | 2020-2025 | Farxiga |
| Acist Medical Systems, INC. | $228.51 | 2024 | |
| Amarin Pharma, INC. | $155.95 | 2019-2020 | |
| Glaxosmithkline, LLC. | $152.98 | 2021-2025 | Arexvy, Shingrix |
| Boston Scientific Corporation | $143.49 | 2019-2025 | Watchman Access System, Watchman Flx, Avvigo Guidance System |
| Gilead Sciences, INC. | $135.33 | 2019-2020 | |
| Esperion Therapeutics, INC. | $124.94 | 2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ayoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.